<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386982</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0103</org_study_id>
    <nct_id>NCT02386982</nct_id>
  </id_info>
  <brief_title>Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients</brief_title>
  <official_title>A Single-centre, Randomized, Open-label, 2-arm, 4-week Treatment Study to Investigate the Beta Cell Function and Related Pharmacodynamics in Type 2 Diabetes Mellitus (T2DM) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and
      tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>beta cell function</measure>
    <time_frame>4 weeks</time_frame>
    <description>will be assessed by change of beta cell function index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour glucose change</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The study drug concentration in blood samples to be collected after drug administration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure of adverse events monitoring, physical examinations,12 lead ECGs, vital sign,and safety laboratory measurement</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 75mg.Oral administration,twice per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMS5552 75mg.Oral administration,once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <other_name>Sinogliatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female,age 18-65 years

          -  Has type 2 diabetes mellitus

          -  BMI 20 to 29kg/m2

          -  Willingness to adhere to the protocol requirement

        Exclusion Criteria:

          -  Patients with type1 diabetes mellitus

          -  Received any antidiabetic drug within run-in or during screening

          -  Hepatic diseases

          -  Kidney diseases

          -  Clinical abnormal finding in EVG,labs and physical exams

          -  Women of child-bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The 1st Betuhune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

